Citations

Mayo Clinic

Showing 10 of 108523 citations.

Real‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia
Rojek, Alexandra E. , McCormick, Benjamin J. , Odetola, Oluwatobi , Nai, Nhi , Foucar, Charles , Achar, Rohan K. , Shallis, Rory M. , Bradshaw, Danielle , Standridge, Meaghan, Badar, Talha , Patel, Anand , Foucar, Charles E , Patel, Anand , Badar, Talha , Rojek, Alexandra E , Cwykiel, Joanna M. , Abaza, Yasmin , Kota, Vamsi , Murthy, Guru Subramanian Guru

eJHaem | July 24, 2024 | Volume: 5 | Issue: 4 | Pages: 728-737

10.1002/jha2.981 | PMID 39157611 Get It

AbstractCore‐binding factor acute myeloid leukemia (CBF‐AML) is characterized by the presence of inv(16)/t(16;16) or t(8;21) and is classified as a favorable risk by the 2022 European LeukemiaNet (ELN) guidelines. The CD33‐targeting antibody‐drug conjugate, gemtuzumab ozogamicin (GO), is commonly added to intensive chemotherapy (IC) in CBF‐AML. We sought to compare outcomes in patients treated with IC with or without GO in CBF‐AML. We included 200 patients with CBF‐AML treated with IC across seven academic centers. Induction treatment regimens were categorized as IC alone, IC with GO, or IC with KIT inhibitor (dasatinib or midostaurin). Median follow‐up for the whole cohort was 2.5 years. Three‐year overall survival (OS) was 70% and 3‐year event‐free survival (EFS) was 51%. Patients treated with IC with GO experienced a 3‐year EFS of 50% compared to those treated with IC alone who experienced a 3‐year EFS of 47%, with no statistically significant difference (p = 0.62). Similarly, those treated with IC with GO did not experience an improved OS compared to those treated with IC alone (p = 0.67). Patients treated with IC with KIT inhibitor experienced a significantly improved 3‐year EFS of 85% compared to those with IC with or without GO (p = 0.04). We find in our study that there is no survival benefit in patients treated with IC with the addition of GO; improved EFS was seen in patients with CBF‐AML treated with IC plus KIT inhibitors, consistent with outcomes noted in prospective studies utilizing this approach.
Integrating Epidemiological Data and Conditional Probabilistic Approaches in Clinical Decision-making: A Focus on Kidney Transplantation
Budhiraja, Pooja , Heilman, Raymond L. , Malamon, John , Budhiraja, Pooja , Schold, Jesse D , Kaplan, Bruce

Transplantation | July 24, 2024 | Volume: 108 | Issue: 11 | Pages: 2159-2161

10.1097/tp.0000000000005160 | PMID 39044330 Get It

Healthcare use around a first dementia diagnosis in older patients with serious mental illness
Chung, Jamie O.P., Woo, Benjamin K P , Shu, Sara, Shu, Sara

Geriatrics & Gerontology International | July 24, 2024 | Volume: 25 | Issue: 1 | Pages: 128-129

10.1111/ggi.14946 | PMID 39044121 Get It

Adjuvant Intralesional Bevacizumab in Pediatric and Adult Populations With Recurrent Respiratory Papillomatosis: A Systematic Review
Gately, Ursula E. , Zhang, Nan , Karle, William E. , Lott, David G. , Lott, David G

Annals of Otology, Rhinology & Laryngology | July 24, 2024 | Volume: 133 | Issue: 10 | Pages: 841-847

10.1177/00034894241264388 | PMID 39044374 Get It

Objective: Recurrent respiratory papillomatosis (RRP) is a rare disease of the airway for which there is no known cure. Treatment involves the surgical removal or destruction of these lesions. There has been a long-standing debate over the effectiveness of the adjuvant intralesional injection of the immune modifying agent bevacizumab. This study is a systematic review investigating the effect of adjuvant intralesional bevacizumab on patients with laryngeal papillomatosis. The main objective was to assess functional outcomes and efficacy. Data Sources: Pubmed, Google Scholar, and Web of Science. Review Methods: Search words were “intralesional bevacizumab” AND “recurrent respiratory papillomatosis.” Sources were systematically identified using inclusion and exclusion criteria (ie, study publication must post-date 2000, must be peer-reviewed, investigate patients with RRP, apply bevacizumab intralesionally, not systemically). Findings were then collected and analyzed. Results: Ten studies were included for analysis. The majority of these studies found an increase in the surgical interval, voice outcomes, and a decrease in tumor burden in most patients. No studies reported side effects or lasting complications related to the bevacizumab injection. Conclusion: This systematic review provides further evidence for the safety of intralesional bevacizumab injections and their likely positive effect on disease control. Future research would benefit from the implementation of standardized documentation of RRP outcomes.
Indications for cerebral revascularization for moyamoya syndrome in pediatric sickle cell disease determined by Delphi methodology
Robert, Adam , Adelson, P. David, Lang, Shih‐Shan , Grabb, Paul A. , Greene, Stephanie , Leonard, Jeffrey, Magge, Suresh N. , Marupudi, Neena I. , Sillero, Rafael de Oliveira , Smith, Edward R. , Smith, Jodi L. , Strahle, Jennifer M. , Vadivelu, Sudhakar , Wellons, John C. , Wrubel, David, Hatem, Asmaa, Moody, C, Han, Sabrina H. , Millican, Nicklaus , Dain, Aleksandra S. , Beslow, Lauren A. , Aldana, Philipp R. , Montaser, Alaa, Smith, Edward , Hanel, Ricardó A. , Johnston, James M. , Piatt, Joseph H. , Hatem, Asmaa, Montaser, Alaa S. , Pederson, John M.

Journal of Neurosurgery: Pediatrics | July 24, 2024 | Volume: 34 | Issue: 4 | Pages: 402-413

10.3171/2024.5.peds2426 | PMID 39029127 Get It

OBJECTIVE Cerebral revascularization surgery (CRS) has been used to prevent stroke in children with sickle cell disease (SCD) and cerebral vasculopathy (e.g., moyamoya syndrome). While results suggest that it may be an effective treatment, surgical indications have not been well defined. This study sought to determine indications for offering revascularization surgery in centers with established sickle cell programs in the US. METHODS Three sequential surveys utilizing the Delphi methodology were administered to neurosurgeons participating in the Stroke in Sickle Cell Revascularization Surgery study. Respondents were presented with clinical scenarios of patients with SCD and varying degrees of ischemic presentation and vasculopathy, and the group’s agreement to offer surgical revascularization was measured. Consensus was defined as ≥ 75% similar responses. RESULTS The response rate to all 3 surveys was 100%. Seventeen neurosurgeons from 16 different centers participated. The presence of moyamoya collaterals (MMCs) and arterial stenosis matching an ischemic distribution yielded the strongest recommendations to offer surgery. There was consensus to offer revascularization in the presence of MMCs and at least 50% arterial stenosis matching an ischemic distribution. In contrast, there was no consensus to offer revascularization with 50%–70% stenosis not matching an ischemic presentation in the absence of MMCs. The presence of the ivy sign in the distribution of the stenotic artery also contributed to the consensus to offer surgery in certain scenarios. CONCLUSIONS There were several clinical scenarios that attained consensus to offer surgery; the strongest was moderate to severe arterial stenosis that matched the distribution of ischemic presentation in the presence of MMCs. Radiological findings of decreased cerebral flow or perfusion also facilitated attaining consensus to offer surgery. The findings of this study reflect expert opinion about questions that deserve prospective clinical research. Determination of indications for CRS can guide clinical practice and aid the design of prospective studies.
Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer’s Disease
McDade, Eric , Hassenstab, Jason , Gordon, Brian A. , Benzinger, Tammie L.S. , Shen, Yuanyuan , Wang, Lihua , Sung, Yun Ju , Daniels, Alisha , Xiong, Chengjie , Perrin, Richard J. , Day, Gregory S. , Chhatwal, Jasmeer P. , Huey, Edward D. , Ryan, Natalie S. , Laske, Christoph , Xiong, Chengjie , Roh, Jee Hoon , Lopera, Francisco , Morris, John C. , Gordon, Brian A , Benzinger, Tammie L S , Sung, Yun Ju , Karch, Celeste M , Renton, Alan , Day, Gregory S , Chhatwal, Jasmeer , Ikeuchi, T , Kasuga, Kensaku , Schofield, Peter R , Brooks, William , Xiong, Chengjie , Roh, Jee Hoon , Bateman, Randall J , Cruchaga, Carlos , Hassenstab, Jason , McDade, Eric M , Morris, John C , Liu, Haiyan , Bui, Quoc Van Phu , Timsina, Jigyasha , Karch, Celeste M. , Morris, John M. , Ibanez, Laura , Llibre‐Guerra, Jorge J. , Supnet, Charlene , Xu, Xiong, Berman, Sarah , Ikeuchi, Takeshi , Niimi, Yoshiki , Schofield, Peter R. , Brooks, William S. , Jucker, Mathias , Vöglein, Jonathan , Lopera, Francisco Javier , Bateman, Randall J.

No container title available | July 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4202125/v1 | PMID 39108475 Get It

Abstract This study explored the role of the ubiquitin-proteasome system (UPS) in dominantly inherited Alzheimer’s disease (DIAD) by examining changes in cerebrospinal fluid (CSF) levels of UPS proteins along with disease progression, AD imaging biomarkers (PiB PET, tau PET), neurodegeneration imaging measures (MRI, FDG PET), and Clinical Dementia Rating® (CDR®). Using the SOMAscan assay, we detected subtle increases in specific ubiquitin enzymes associated with proteostasis in mutation carriers (MCs) up to two decades before the estimated symptom onset. This was followed by more pronounced elevations of UPS-activating enzymes, including E2 and E3 proteins, and ubiquitin-related modifiers. Our findings also demonstrated consistent correlations between UPS proteins and CSF biomarkers such as Aβ42/40 ratio, total tau, various phosphorylated tau species to total tau ratios (ptau181/T181, ptauT205/T205, ptauS202/S202, ptauT217/T217), and MTBR-tau243, alongside Neurofilament light chain (NfL) and the CDR®. Notably, a positive association was observed with imaging markers (PiB PET, tau PET) and a negative correlation with markers of neurodegeneration (FDG PET, MRI), highlighting a significant link between UPS dysregulation and neurodegenerative processes. The correlations suggest that the increase in multiple UPS proteins with rising tau levels and tau-tangle associated markers, indicating a potential role for the UPS in relation to misfolded tau/neurofibrillary tangles (NFTs) and symptom onset. These findings indicate that elevated CSF UPS proteins in DIAD MCs could serve as early indicators of disease progression and suggest a link between UPS dysregulation and amyloid plaque, tau tangles formation, implicating the UPS as a potential therapeutic target in AD pathogenesis.
Impact of Workplace Violence Against Emergency Medical Services (EMS)
McGuire, Sarayna S. , Clements, Casey M. , Lampman, Michelle A. , Smith, Olivia A, McGuire, Sarayna S , Smith, Olivia A.

Prehospital Emergency Care | July 23, 2024 | Volume: 29 | Issue: 2 | Pages: 129-137

10.1080/10903127.2024.2381218 | PMID 39042823 Get It

Three-dimensional printing for complex cardiac reoperations: optimising Gerbode defect repairs
Khan, Fazal Wahab , Chopko, Trevor C. , Maltais, Simon, Stulak, John M., Khan, Fazal W, Chopko, Trevor

BMJ Case Reports | July 23, 2024 | Volume: 17 | Issue: 7 | Pages: e260689

10.1136/bcr-2024-260689 | PMID 39043460 Get It

Cardiac fistulas present diagnostical and therapeutical challenges due to their variability in size, shape and pathway. Three-dimensional printing is increasingly used to provide a tactile representation that aids in preoperative planning and patient education. We present the case of a female in her 60s who developed a fistula between the left ventricle, right atrium and coronary sinus 2 years after bioprosthetic valve replacement. We used three-dimensional modelling to better understand her cardiac anatomy and optimise our surgical approach. She was discharged home without deficit following an uneventful postoperative course. Three-dimensional printing can improve patient care through tangible demonstration, preoperative planning and trainee education.
Defining the tipping point for revision reverse shoulder arthroplasty
Buchanan, Timothy R. , Hao, Kévin A. , Cueto, Robert J. , O’Keefe, Daniel S. , Hones, Keegan M. , Krisanda, Emily, Wright, Jonathan O. , Wright, Thomas W. , Struk, Aimee M., S O'Keefe, Daniel , Wright, Jonathan O , Schoch, Bradley S , King, Joseph J , Hao, Kevin A , Hones, Keegan M , Bindi, Victoria E. , Farmer, Kevin W. , Schoch, Bradley S. , King, Joseph J.

Shoulder & Elbow | July 23, 2024 | Volume: 17 | Issue: 4 | Pages: 439-449

10.1177/17585732241263753 | PMID 39552664 Get It

Background This study sought to characterize the tipping point values (the functional scores that patients deem dysfunctional enough to warrant surgery) for patients undergoing first revision reverse total shoulder arthroplasty (rTSA). Methods This study was a retrospective review of a prospectively collected single-institution database of patients undergoing first revision rTSA between August 2015 and December 2019. Tipping point evaluation utilized preoperative scores including the American Shoulder and Elbow Surgeons (ASES), raw and normalized Constant, Shoulder Pain and Disability Index (SPADI), Simple Shoulder Test (SST), and University of California-Los Angeles (UCLA) scores, and active range of motion including abduction, forward elevation (FE), external rotation (ER), and internal rotation score (IR) prior to elective revision rTSA. Results We included 125 revision rTSAs. Tipping points were 37.6 ASES score, 30.5 raw Constant score, 35.5 normalized Constant score, 68.1 SPADI, 3.7 SST, 13.2 UCLA score, 64° abduction, 69° FE, 23° ER, and 3.1 IR. Higher SST was found for older patients and patients with a lower body mass index. Lower abduction and FE tipping points were reported in patients undergoing revision rTSA for rotator cuff failure, unexplained pain, and implant wear. Discussion These tipping points can help surgeons counsel patients regarding when to undergo revision rTSA. Level of evidence Level III; retrospective cohort study; treatment study.